deva-amoxyclav 400/57 amoxicillin 400mg (as trihydrate) and clavulanic acid 57mg (as potassium clavulanate) powder for oral suspension bottle
devatis pty ltd - amoxicillin trihydrate, quantity: 91.823 mg/ml; potassium clavulanate, quantity: 13.58 mg/ml - suspension, powder for - excipient ingredients: saccharin sodium; xanthan gum; methyl hydroxybenzoate; succinic acid; colloidal anhydrous silica; silicon dioxide; hypromellose; flavour - deva-amoxyclav 400/57 (amoxicillin and clavulanic acid) oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology):,skin and skin structure infections,urinary tract infections (complicated and uncomplicated),upper respiratory tract infections including sinusitis and otitis media,lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to deva-amoxyclav 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to deva-amoxyclav 400/57, should not require the addition of another antibiotic due to the amoxicillin content of deva-amoxyclav 400/57.
terry white chemists amoxycillin and clavulanic acid 875mg/125mg tablet blister pack
apotex pty ltd - amoxicillin trihydrate,potassium clavulanate -
chemmart amoxycillin and clavulanic acid 875mg/125mg tablet blister pack
apotex pty ltd - amoxicillin trihydrate,potassium clavulanate -
amoxyclav an 875/125 amoxicillin (as trihydrate) 875 mg and clavulanic acid (as potassium clavulanate) 125 mg tablet blister pac
southern cross pharma pty ltd - amoxicillin trihydrate,potassium clavulanate -
amoxyclav an 500/125 amoxicillin (as trihydrate) 500 mg and clavulanic acid (as potassium clavulanate) 125 mg tablet blister pac
southern cross pharma pty ltd - amoxicillin trihydrate,potassium clavulanate -
amoxicillin and clavulanate potassium- amoxicillin and clavulanate potassium powder, for suspension
nucare pharmaceuticals,inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanic acid (unii: 23521w1s24) (clavulanic acid - unii:23521w1s24) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium powder for oral suspension, usp (amoxicillin/clavulanate potassium) and other antibacterial drugs, amoxicillin and clavulanate potassium powder for oral suspension, usp should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium powder for oral suspension, usp is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: - caused by beta-lactamase-producing isolates of haemophilus
amoxicillin and clavulanate potassium- amoxicillin and clavulanate potassium powder, for suspension
nucare pharmaceuticals,inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanic acid (unii: 23521w1s24) (clavulanic acid - unii:23521w1s24) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium powder for oral suspension, usp (amoxicillin/clavulanate potassium) and other antibacterial drugs, amoxicillin and clavulanate potassium powder for oral suspension, usp should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium powder for oral suspension, usp is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: - caused by beta-lactamase-producing isolates of haemophilus
amoxiclav teva 250 - 62,5 mg or. susp. (pwdr.)
teva pharma belgium sa-nv - amoxicillin trihydrate 287 mg - eq. amoxicillin 250 mg; clavulanic acid 74,45 mg - powder for oral suspension - 250 - 62,5 mg - clavulanic acid 74.45 mg; amoxicillin trihydrate 287 mg - amoxicillin and enzyme inhibitor
amoxiclav teva 500 mg - 125 mg film-coat. tabl.
teva pharma belgium sa-nv - amoxicillin trihydrate 574 mg - eq. amoxicillin 500 mg; clavulanic acid 148,9 mg - film-coated tablet - 500 - 125 mg - clavulanic acid 148.9 mg; amoxicillin trihydrate 574 mg - amoxicillin and enzyme inhibitor
amoxicillin/clavulanic acid 500/125 milligram film coated tablet
rowex ltd - amoxicillin trihydrate clavulanate potassium - film coated tablet - 500/125 milligram